Elsevier

American Heart Journal

Volume 170, Issue 2, August 2015, Pages 263-272.e2
American Heart Journal

Clinical Investigation
Acute Ischemic Heart Disease
Trends in characteristics of cardiovascular clinical trials 2001-2012

https://doi.org/10.1016/j.ahj.2015.05.006Get rights and content

Background

Efficient conduct of clinical trials is essential for the timely generation of critical medical knowledge.

Methods

We systematically assessed size, duration, enrollment rates, and geographic distribution of randomized cardiovascular trials published between 2001 and 2012 in the 8 highest-impact journals in general medicine and cardiology.

Results

Of the 1,224 trials, 27.0% were conducted in North America, 36.5% in Western Europe, and 7.7% in other countries, and 28.8% were multiregional. Trials enrolled a median of 452 patients (interquartile range 167-1,530) in 20 sites (2-76). Median duration was 2.1 (1.3-3.3) years, with an estimated enrollment rate of 1.1 (0.5-3.5) patients/site per month. Between 2001-2003 and 2009-2012, the proportion of North American trials decreased from 34.5% to 25.7% (P = .006), whereas that of multiregional trials (from 26.0% to 30.3%; P = .046) and trials conducted in other countries (from 4.6% to 10.3%; P = .012) increased. Over time, trials involved more patients (from 400 to 500 [median]; P = .032) and sites (from 20 to 22; P = .049), multiregional trials involved more countries (from 12 to 18; P = .031), and enrollment rate declined from 1.2 to 0.9 patients/site per month (P = .017). The proportion of trials meeting their primary end point (“positive”) decreased from 69% to 57% (P < .001). Trials with higher enrollment rates were more likely to be positive (odds ratio 1.20 per doubling, 95% CI 1.12-1.29), as were industry-sponsored compared with government-sponsored trials (odds ratio 2.62, 95% CI 1.67-4.12).

Conclusions

From 2001 to 2012, cardiovascular clinical trials have become larger, more global, and less likely to meet their primary end point. Enrollment rates have declined, requiring more sites and regions.

Section snippets

Identification of clinical trials

We reviewed all trials in cardiovascular medicine published between 2001 and 2012 in the 8 journals with the highest Web of Science impact factor in the categories “general and internal medicine” and “cardiology,” according to the 2013 edition of the Journal Citation Reports, including the New England Journal of Medicine, the Journal of the American Medical Association, Lancet, Annals of Internal Medicine, Circulation, European Heart Journal, the Journal of the American College of Cardiology,

Publication sources and interventions studied

We identified 1,224 RCTs that cumulatively enrolled 2,350,632 participants in 98 countries (Figure 1). Of these, 267 (21.8%) were published in New England Journal of Medicine, 257 (21.0%) in Circulation, 214 (17.5%) in Journal of the American College of Cardiology), 166 (13.6%) in Lancet, 150 (12.2%) in Journal of the American Medical Association, and the remaining (13.9%) in Annals of Internal Medicine, British Medical Journal, and European Heart Journal. The most common intervention was a

Discussion

For cardiovascular clinical trials published in premier general medical and cardiology journals between 2001 and 2012, we observed that over time (1) enrollment rate decreased by ≈25%, (2) more sites were required to complete trials, and (3) trials have increased in size and geographic scope. In addition, universities or organizations funded a larger proportion of trials over time. These are important findings, considering the profound impact of RCTs on practice.

Successful conduct of RCTs

Disclosures

Dr Butler is a consultant to Amgen, Bayer, BG Medicine, Celladon, Gambro, GE Healthcare, Harvest, Medtronic, Ono Pharma, Stemedica, and Trevena. Dr Peterson reports significant research grant support from Eli Lilly & Company and Janssen Pharmaceuticals, Inc, and modest consultant/advisory board support from Boehringer Ingelheim, Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc, Pfizer, and Genentech Inc. Dr Fonarow reports significant consultant support from Novartis and Takeda, and modest

References (35)

  • R.M. Califf et al.

    American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy?

    J Am Coll Cardiol

    (2011)
  • S. Homma et al.

    Warfarin and aspirin in patients with heart failure and sinus rhythm

    N Engl J Med

    (2012)
  • S.W. Glickman et al.

    Ethical and scientific implications of the globalization of clinical research

    N Engl J Med

    (2009)
  • Committee on Cancer Clinical Trials the NCI Cooperative Group Program Institute of Medicine. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program

    (2010)
  • A.C. Gelijns et al.

    Looking beyond translation—integrating clinical research with medical practice

    N Engl J Med

    (2012)
  • E.A. Largent et al.

    Can research and care be ethically integrated?

    Hast Cent Rep

    (2011)
  • K.A. Getz

    Global clinical trials activity in the details. Applied clinical trials. September 1, 2007

  • Cited by (24)

    • Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory

      2018, Journal of the American College of Cardiology
      Citation Excerpt :

      There appears to be a myriad of causes. Poor patient enrollment leads to slow and costly clinical trials (2). A number of factors influence patients’ decisions to participate in clinical research, including trial complexity and burden, a favorable benefit to risk profile for the experimental treatment, and the potential to help others (3).

    • Defining Advanced Heart Failure: A Systematic Review of Criteria Used in Clinical Trials

      2016, Journal of Cardiac Failure
      Citation Excerpt :

      In fact, in our study, we observed a relaxation of LVEF criteria and increasing average LVEF of patients included in advanced HF trials over time. This might reflect the increasing difficulties in achieving enrollment targets in ever-larger cardiovascular clinical trials attempting to meet endpoints for diminishing efficacy margins.12,13 In turn, this creates a clear discrepancy between advanced HF definitions for clinical practice, in which a primary concern is patient identification and referral for advanced therapies, and clinical trial purposes.

    • Trends in Heart Failure Clinical Trials from 2001-2012

      2016, Journal of Cardiac Failure
      Citation Excerpt :

      Our study demonstrated that enrollment rates were persistently low over time, at <0.7 patients site−1 month−1. These rate estimates appear to be even lower than contemporaneously conducted general cardiovascular trials and are paradoxically low considering the tremendous prevalence of HF in the general population.9 Moreover, the excess costs and resources incurred by slow trial enrollment may influence patient profiles and trial outcomes.6

    View all citing articles on Scopus

    Funding sources: None.

    View full text